Tangeretin as an adjuvant and chemotherapeutic sensitizer against various types of cancers: a comparative overview
Authors:
Open Access
- 4 March 2021
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 73 (5) , 601-610
Abstract
Objectives: Cancer is a leading cause of disabling morbidities and death worldwide. Although there are various strategies for the management of cancer, the severe adverse effects negatively impact the patient’s quality of life. In addition, the development of resistance limits the efficacy of many chemotherapeutics. Many natural agents are capable of reducing the adverse effects associated with chemotherapy and improving the therapeutic outcome. Tangeretin, a polymethoxy flavone, is one of the promising natural anticancer agents. Key findings: Tangeretin not only targets various malignancies but also synergizes chemotherapeutic agents and reverses cancer resistance. Hence, the application of tangeretin as an adjuvant in cancer chemotherapy would be a promising strategy. Summary: This work critically highlighted the proposed anticancer activity of tangeretin and discussed its potential combination with various chemotherapeutic agents. Additionally, it shed light on tangeretin chemical derivatives with improved pharmacokinetic and pharmacodynamic activity. Finally, this review described flavonoid biosynthetic pathways and how bioengineering can be employed to enhance the production yield of tangeretin. Thus, this work paves the way for the rational clinical utilization of tangeretin as a safe and effective adjuvant in chemotherapeutic protocols.Keywords
Funding Information
- Al Jalila Foundation, United Arab Emirates (AJF2018050)
This publication has 72 references indexed in Scilit:
- De novo production of the flavonoid naringenin in engineered Saccharomyces cerevisiaeMicrobial Cell Factories, 2012
- Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo anti-metastatic activitiesCancer and Metastasis Reviews, 2012
- The p53‐, Bax‐ and p21‐dependent inhibition of colon cancer cell growth by 5‐hydroxy polymethoxyflavonesMolecular Nutrition & Food Research, 2010
- The flavonoid tangeretin activates the unfolded protein response and synergizes with imatinib in the erythroleukemia cell line K562Molecular Nutrition & Food Research, 2010
- Tangeretin Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Downregulation of Phosphoinositide 3-Kinase/Akt Signaling PathwayCancer Research, 2009
- Bioavailability of Polymethoxyflavones2008
- Tangeretin suppresses IL-1β-induced cyclooxygenase (COX)-2 expression through inhibition of p38 MAPK, JNK, and AKT activation in human lung carcinoma cellsBiochemical Pharmacology, 2007
- Fruit and Vegetable Juices and Alzheimer’s Disease: The Kame ProjectThe American Journal of Medicine, 2006
- Tangeretin inhibits extracellular‐signal‐regulated kinase (ERK) phosphorylationFEBS Letters, 2005
- Natural flavonoids and lignans are potent cytostatic agents against human leukemic HL-60 cellsLife Sciences, 1994